Jonathan Rothbard
Chief Executive Officer at Katexco Pharmaceuticals Corp.
Net worth: 2 609 $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Marc Feldmann | M | 79 |
Katexco Pharmaceuticals Corp.
 Katexco Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Katexco Pharmaceuticals Corp. operates as medical marijuana company that engages in the development of orally available therapies harnessing endocannabinoid and nicotine receptors to treat inflammatory diseases. The company was founded by Jonathan Rothbard, Lawrence Steinman and Marc Feldmann and is headquartered in Toronto, Canada.
CannBioRex Pharmaceuticals Corp.
 CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 years |
| Lawrence Pemble | M | 36 |
Katexco Pharmaceuticals Corp.
Katexco Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Katexco Pharmaceuticals Corp. operates as medical marijuana company that engages in the development of orally available therapies harnessing endocannabinoid and nicotine receptors to treat inflammatory diseases. The company was founded by Jonathan Rothbard, Lawrence Steinman and Marc Feldmann and is headquartered in Toronto, Canada.
CannBioRex Pharmaceuticals Corp.
CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 years |
| Nick DeMare | M | 69 |
Katexco Pharmaceuticals Corp.
Katexco Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Katexco Pharmaceuticals Corp. operates as medical marijuana company that engages in the development of orally available therapies harnessing endocannabinoid and nicotine receptors to treat inflammatory diseases. The company was founded by Jonathan Rothbard, Lawrence Steinman and Marc Feldmann and is headquartered in Toronto, Canada.
CannBioRex Pharmaceuticals Corp.
CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 years |
| Lawrence Steinman | M | 76 |
Katexco Pharmaceuticals Corp.
Katexco Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Katexco Pharmaceuticals Corp. operates as medical marijuana company that engages in the development of orally available therapies harnessing endocannabinoid and nicotine receptors to treat inflammatory diseases. The company was founded by Jonathan Rothbard, Lawrence Steinman and Marc Feldmann and is headquartered in Toronto, Canada.
CannBioRex Pharmaceuticals Corp.
CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 years |
| David Danziger | M | 67 |
CannBioRex Pharmaceuticals Corp.
CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 years |
| Augusto Steve Legasto | M | 78 |
The Trustees of Columbia University in The City of New York
| 53 years |
| Roger Daher | M | 58 |
CannBioRex Pharmaceuticals Corp.
CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 years |
| Charanjit Bountra | M | 63 |
CannBioRex Pharmaceuticals Corp.
CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 years |
| Raphael Mechoulam | M | - |
CannBioRex Pharmaceuticals Corp.
CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 years |
| Donald Quest | M | 83 |
The Trustees of Columbia University in The City of New York
| 48 years |
| Richard Williams | M | 67 |
CannBioRex Pharmaceuticals Corp.
CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Lupo Rattazzi | M | 71 |
The Trustees of Columbia University in The City of New York
| 4 years |
| Hus Tigli | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| John R. Rehayem | M | - |
The Trustees of Columbia University in The City of New York
| 6 years |
| Thomas W. Mossberg | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Richard Andersen | M | - |
The Trustees of Columbia University in The City of New York
| 7 years |
| Anders Klein | M | 71 |
The Trustees of Columbia University in The City of New York
| 6 years |
| Maria Matesanz | F | - |
The Trustees of Columbia University in The City of New York
| 5 years |
| Carolyn Nannini Dolan | F | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Frank Falco | M | - |
The Trustees of Columbia University in The City of New York
| 5 years |
| Ed F. Schnipper | M | 75 |
Cellgate, Inc.
 Cellgate, Inc. Pharmaceuticals: MajorHealth Technology Progen Pharmaceuticals, Inc. develops biopharmaceuticals products. It is engaged in developing improved drug delivery based on their transporter molecules. The company is headquartered in Redwood City, CA. | 6 years |
| John Roglieri | M | 84 |
The Trustees of Columbia University in The City of New York
| 4 years |
| Gary Davis | M | - |
The Trustees of Columbia University in The City of New York
| 3 years |
| Joshua S. Rubenstein | M | - |
The Trustees of Columbia University in The City of New York
| 7 years |
| Chani Pangali | M | - |
The Trustees of Columbia University in The City of New York
| 3 years |
| Laurence Marton | M | 80 |
Cellgate, Inc.
Cellgate, Inc. Pharmaceuticals: MajorHealth Technology Progen Pharmaceuticals, Inc. develops biopharmaceuticals products. It is engaged in developing improved drug delivery based on their transporter molecules. The company is headquartered in Redwood City, CA. | 5 years |
| Fred W. Hill | M | 73 |
The Trustees of Columbia University in The City of New York
| 2 years |
| Jaiye Oyedotun | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Alexander H. Platt | M | - |
The Trustees of Columbia University in The City of New York
| 3 years |
| Theodore Marshall Helms | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Jacob Dagan | M | 79 |
The Trustees of Columbia University in The City of New York
| 3 years |
| Arthur S. Adler | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Young-Jin Kim | M | 74 |
The Trustees of Columbia University in The City of New York
| 2 years |
| Stuart Graham Arthur | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Alfonso Rebuelta Badías | M | 71 |
The Trustees of Columbia University in The City of New York
| 2 years |
| Tommy Thompson | M | 71 |
The Trustees of Columbia University in The City of New York
| 4 years |
| Mark Lebwohl | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Kenneth J. DeWoskin | M | - |
The Trustees of Columbia University in The City of New York
| 3 years |
| Bruce D. Carpenter | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Clyde L. Briant | M | - |
The Trustees of Columbia University in The City of New York
| 1 years |
| Alan R. Abrams | M | 69 |
The Trustees of Columbia University in The City of New York
| 4 years |
| Wahab Dabiri | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Anthony Mario Ianni | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Ken Birman | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Wang Kwong Luk | M | 79 |
The Trustees of Columbia University in The City of New York
| 4 years |
| James Edward McGreevey | M | 66 |
The Trustees of Columbia University in The City of New York
| 4 years |
| Kevin Michael O'Conner | M | - |
The Trustees of Columbia University in The City of New York
| 1 years |
| Michael C. Attipoe | M | - |
The Trustees of Columbia University in The City of New York
| 1 years |
| Lolita Mancheno-Smoak | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| H. Merritt | M | - |
The Trustees of Columbia University in The City of New York
| 3 years |
| Mary A. Mullin | F | - |
The Trustees of Columbia University in The City of New York
| 1 years |
| Nitin Dalal | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Joseph A. Sullivan | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Bernard W. Gray | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| Ray Duggins | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Lawrence Riddles | M | - |
The Trustees of Columbia University in The City of New York
| 1 years |
| Alan R. Dietrich | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Ka Shuen Wen | M | 70 |
The Trustees of Columbia University in The City of New York
| 4 years |
| Tony Carrion | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| John Regazzi | M | 76 |
The Trustees of Columbia University in The City of New York
| 2 years |
| Alan N. Waxman | M | - |
The Trustees of Columbia University in The City of New York
| 3 years |
| Simon Luk | M | - |
The Trustees of Columbia University in The City of New York
| 3 years |
| Takeshi Odagi | M | 81 |
The Trustees of Columbia University in The City of New York
| 3 years |
| Moira J. McGrane | F | - |
The Trustees of Columbia University in The City of New York
| 3 years |
| Bob Deresiewicz | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Fred Kittler | M | 75 |
The Trustees of Columbia University in The City of New York
| 4 years |
| Raymond T. Leung | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Dave H. Treitel | M | - |
The Trustees of Columbia University in The City of New York
| 1 years |
| John S. Russell | M | 69 |
The Trustees of Columbia University in The City of New York
| 1 years |
| Jim A. Pelusi | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Alessandro A. Piol | M | 67 |
The Trustees of Columbia University in The City of New York
| 4 years |
| Marcia J. Hooper | F | 69 |
The Trustees of Columbia University in The City of New York
| 2 years |
| David C. Colby | M | 70 |
The Trustees of Columbia University in The City of New York
| 4 years |
| Michael German | M | 73 |
The Trustees of Columbia University in The City of New York
| 2 years |
| Marc Mazur | M | 64 |
The Trustees of Columbia University in The City of New York
| 4 years |
| Jack J. Hersch | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Robert Sachs | M | 76 |
The Trustees of Columbia University in The City of New York
| 1 years |
| Tom Glocer | M | 63 |
The Trustees of Columbia University in The City of New York
| 4 years |
| Richard Baer | M | 67 |
The Trustees of Columbia University in The City of New York
| 4 years |
| Kevin William Jakeway | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Howard R. Friedner | M | - |
The Trustees of Columbia University in The City of New York
| 5 years |
| Michael Idelchik | M | 71 |
The Trustees of Columbia University in The City of New York
| 4 years |
| Eli Gang | M | - |
The Trustees of Columbia University in The City of New York
| 3 years |
| Lewis B. Kaden | M | 81 |
The Trustees of Columbia University in The City of New York
| 8 years |
| José Francisco Gouvêa Vieira | M | 74 |
The Trustees of Columbia University in The City of New York
| 3 years |
| Evan Miller | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Yash Aggarwal | M | - |
The Trustees of Columbia University in The City of New York
| 3 years |
| Charles B. Seelig | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| George J. Tenet | M | 71 |
The Trustees of Columbia University in The City of New York
| 1 years |
| James C. Colihan | M | - |
The Trustees of Columbia University in The City of New York
| 1 years |
| Kenneth P. Kopelman | M | 72 |
The Trustees of Columbia University in The City of New York
| 3 years |
| Maarten Das | M | 75 |
The Trustees of Columbia University in The City of New York
| 3 years |
| James Rasulo | M | 68 |
The Trustees of Columbia University in The City of New York
| 4 years |
| Noel Kropf | M | - |
The Trustees of Columbia University in The City of New York
| 5 years |
| Michael M. Meadvin | M | - |
The Trustees of Columbia University in The City of New York
| 3 years |
| Seth Haberman | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Patrick Combes | M | 71 |
The Trustees of Columbia University in The City of New York
| 2 years |
| Keith Chan | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Paul C. Christopherson | M | - |
The Trustees of Columbia University in The City of New York
| 2 years |
| David Paterson | M | 70 |
The Trustees of Columbia University in The City of New York
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 91 | 91.00% |
| Canada | 9 | 9.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jonathan Rothbard
- Personal Network
